Anthropic Acquires AI Biotech Startup Coefficient Bio in $400M Deal to Revolutionize Drug Discovery

Anthropic has acquired Coefficient Bio, a stealth biotech AI startup, in a $400 million stock deal reported on April 3, 2026.

This move accelerates Anthropic's expansion into healthcare and life sciences.

Company Backgrounds

Anthropic, renowned for its AI models, launched Claude for Life Sciences last October to support scientific breakthroughs.

Coefficient Bio was founded eight months ago by ex-Genentech researchers Samuel Stanton and Nathan C. Frey.

The startup's team of about 10 focused on AI tools to streamline drug discovery and biological research.

The deal bolsters Anthropic's expertise in applying AI to biotech challenges like efficient drug development.

Coefficient Bio's team will join Anthropic’s health and life sciences group for seamless integration.

This acquisition highlights the growing convergence of AI and biotech, promising faster innovations in medicine.

Historically, such AI-biotech mergers have reduced drug development timelines and costs significantly.

Looking forward, Anthropic could lead in AI-driven personalized therapies and novel treatments.

The biotech industry anticipates transformative changes from this high-profile union.

Written by

Journalist

BEAMSTART Membership

Get the stories founders act on, plus $1M+ in perks.